Elonva, infertility treatment by MSD-Korea, the Korean branch of the Merck & Co., gained the Korea Food and Drug Administration’s approval last week, the company said Monday.
The follitropin beta (gene recombination)-based injection was proven effective for controlled ovarian stimulation (COS) on women receiving assisted reproductive technology.
The drug can replace the seven-session injection of recombinant follicle stimulating hormone in the first week of COS, the company said.
